Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9821 in Moderate to Severe COPD
NCT07640451Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-9821 in chronic obstructive pulmonary disease (COPD), sponsored by Hengrui Therapeutics. Started Jul 2026; status: recruiting.
02
Drugs
HRS-9821
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07640451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640451.